Advertisement
Advertisement
PMCB
PharmaCyte Biotech, Inc. Common Stock
0.76
USDSponsored
-0.04
-5.53%
May 08, 15:59 UTC -4
Closed
After-Market
0.77
+0.01
+1.48%
PMCB Earnings Reports
Positive Surprise Ratio
PMCB beat 2 of 4 last estimates.
50%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue
On Mar 16, 2026, PMCB reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Quoin Pharmaceuticals, Ltd. - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.96
Actual
-$1.77
Surprise
+9.93%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
FAQ
What were PharmaCyte Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, PharmaCyte Biotech, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to PharmaCyte Biotech, Inc. Common Stock's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is PharmaCyte Biotech, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for PharmaCyte Biotech, Inc. Common Stock's next earnings report?
Based on --
analysts, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement